Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

23,630 total articles

Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) has signed a strategic agreement to merge with ITM Isotope Technologies Munich SE, a global leader in therapeutic radioisotope production. The merger enhances Telix's vertical integration by combining ITM's profitable, commercial-scale isotope manufacturing and an extensive therapeutic pipeline includin…

Qfin Holdings Announces Changes in Management and Board Composition

Qfin Holdings Announces Changes in Management and Board Composition

Qfin Holdings, a leading AI-driven credit-tech platform in China, announced a leadership transition with Yan Zheng appointed as the new CEO, succeeding Haisheng Wu. Mr. Wu will focus on the company's growing international business, while Mr. Zheng brings 18 years of consumer finance risk management experience to the role. The board endorsed the smo…

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

Cue Biopharma announced positive topline Phase 2 results for CUE-221, an anti-IgE antibody, demonstrating statistically significant efficacy and a favorable safety profile in patients with moderate to severe chronic spontaneous urticaria (CSU). The study indicated dose-responsive improvement that surpasses omalizumab (XOLAIR) at highest doses, sugg…

MISSION SUCCESS: Rocket Lab Launches 96th Electron Mission

MISSION SUCCESS: Rocket Lab Launches 96th Electron Mission

Rocket Lab Corporation successfully completed its 96th Electron launch, deploying the 12th StriX satellite into low Earth orbit for Synspective's Earth-monitoring SAR satellite constellation. This marks Rocket Lab's 17th launch in 2026 and maintains a perfect mission success record with Synspective. The company plans 15 more dedicated Electron laun…

Greenland Mines Applauds Historic U.S.-Denmark-Greenland Security Agreement, Reinforcing Greenland’s Strategic Importance to the United States

Greenland Mines Applauds Historic U.S.-Denmark-Greenland Security Agreement, Reinforcing Greenland’s Strategic Importance to the United States

Greenland Mines Ltd applauds the historic security agreement between the US, Denmark, and Greenland that expands US presence and limits adversaries' military and investment activities in Greenland. The company highlights Greenland's strategic value, particularly its significant rare earth and precious metal mineral assets critical for defense and e…

Home BancShares, Inc. Announces Recognition in Forbes Top-Performing Banks and Bank Director RankingBanking

Home BancShares, Inc. Announces Recognition in Forbes Top-Performing Banks and Bank Director RankingBanking

Home BancShares, Inc., parent company of Centennial Bank, was recognized by Forbes and Bank Director for its strong performance among mid-size U.S. banks. Forbes ranked HOMB #5 in Mid-Size Banks based on profitability, growth, capital resilience, and asset quality. Bank Director ranked it #9 in the $5-$50 billion asset group and #18 among the top 2…

New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients

New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients

Teva Pharmaceutical Industries Ltd. released new data highlighting key attributes that healthcare providers prioritize when selecting treatments for tardive dyskinesia (TD) in patients aged 55 and older. The study found that providers value low drowsiness risk, demonstrated long-term efficacy, and favorable drug-drug interaction profiles. Teva's AU…

Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs

Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs

Teva Pharmaceuticals announced new real-world evidence demonstrating that UZEDY® (risperidone) extended-release injectable suspension helps schizophrenia and bipolar I disorder patients maintain longer treatment adherence compared to other long-acting injectables and oral antipsychotics. The studies showed UZEDY reduces emergency department visits,…

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

Teva Pharmaceutical Industries Ltd. announced positive post hoc data from its Phase 3 SOLARIS trial evaluating TEV-'749, a once-monthly subcutaneous long-acting injectable formulation of olanzapine for the treatment of adults with schizophrenia. The data demonstrate high rates of patient stabilization, low relapse rates, and sustained remission ove…

Enact Receives Ratings Upgrade from AM Best

Enact Receives Ratings Upgrade from AM Best

Enact Holdings, Inc., a leading U.S. private mortgage insurance provider, announced that AM Best upgraded its insurance financial strength rating from A- to A and elevated its long-term issuer rating from bbb- to bbb, with a stable outlook. This marks Enact's first rating upgrade since coverage began in 2023, reflecting its consistent execution and…

XCharge Reports First Half 2026 Unaudited Financial Results

XCharge Reports First Half 2026 Unaudited Financial Results

XCHG Limited (Nasdaq: XCH), a global provider of high-power EV charging solutions, released its unaudited financial results for the first half of 2026. Revenues decreased by 17.5% to $10.3 million due to customer procurement timing and project schedule changes, resulting in an operating loss of $11.2 million. The company launched new products, esta…

Amneal Announces FDA Approval and Launch of Lanreotide Injection

Amneal Announces FDA Approval and Launch of Lanreotide Injection

Amneal Pharmaceuticals announced FDA approval and immediate launch of its lanreotide injection, a long-acting oncology treatment for acromegaly, GEP-NETs, and carcinoid syndrome. The product has Competitive Generic Therapy designation and is expected to drive growth by expanding Amneal's complex injectables portfolio supported by in-house manufactu…

Roundtable Clarifies Structure, Equity and Economics of 10-Year, $1 Billion Platform Partnership

Roundtable Clarifies Structure, Equity and Economics of 10-Year, $1 Billion Platform Partnership

Roundtable has detailed its 10-year, $1 billion strategic partnership with Paradium.AI to migrate and monetize Paradium.AI’s premium media portfolio on Roundtable’s AI/DeFi-powered platform. This partnership involves a minority share investment (not an acquisition) and aims to create a $100 million annual advertising ecosystem with high margins and…

Research Frontiers Welcomes Gauzy’s Court-Approved Restructuring and the Restart of SPD-Smart Light Control Film Production

Research Frontiers Welcomes Gauzy’s Court-Approved Restructuring and the Restart of SPD-Smart Light Control Film Production

Research Frontiers Inc., a developer and licensor of patented SPD-SmartGlass technology, praised Gauzy Ltd.'s court-approved debt restructuring and restart of SPD light-control film production in Germany and Israel. This milestone enables continued supply and development of SPD products for automotive, aircraft, marine, and architectural markets, s…

BCB Bancorp, Inc. Announces Closing of Public Offering and Full Exercise of Underwriter’s Over-Allotment Option, for Aggregate Gross Proceeds of $98 Million

BCB Bancorp, Inc. Announces Closing of Public Offering and Full Exercise of Underwriter’s Over-Allotment Option, for Aggregate Gross Proceeds of $98 Million

BCB Bancorp, Inc. successfully closed an underwritten public offering of 12.65 million shares, including full exercise of the underwriter's option, raising roughly $98 million gross proceeds. The company plans to use proceeds to maintain liquidity, support bank capital, reduce debt, and address problem loans, reinforcing its financial position amid…